FLT3 Mutation Status is a Predictor of Early Death in Pediatric Acute Promyelocytic Leukemia: A Report From The Children's Oncology Group

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations had a significantly lower complete remission rate after first induction (60%) compared to FLT3 wild-type patients (93%), driven primarily by induction deaths

Effect: decline; 60% vs 93%

Among pediatric APL patients who survived induction and achieved complete remission, FLT3 mutation status was not associated with differences in overall survival, event-free survival, or relapse-free

Effect: null

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%